Stroke
July 2015 using the following search terms: stroke or cerebrovascular disease or cerebrovascular attack or cerebral ischemia or brain infarct or transient ischemic attack AND antihypertensive therapy or blood pressure lowering or blood pressure reduction or thiazide or β-antagonists or α-antagonist or angiotensin-converting enzyme inhibitors or angiotensin antagonists or angiotensin inhibitors or calcium channel blockers AND acute or early or immediate or rapid. We restricted our search to human beings and clinical trials. There were no language restrictions. We also reviewed the introduction and discussion sections of retrieved trials and prior meta-analysis 5 to identify additional trials. Some data not provided by original articles but published in the latest Cochrane Review were also used. 7 
Study Selection
The cutoff of 3 days for blood pressure lowering intervention to be considered started in the early time period was chosen pragmatically. In the absence of a universally accepted threshold, this threshold was considered physiologically reasonable and had been previously used in an analysis of a subgroup of a large clinical trial, The Prevention Regimen for Effectively Avoiding Second Stroke (PRoFESS). 8 Also, studies were selected when they met the following entry criteria: (1) studies were RCTs; (2) all participants in the study or in a separately reported subgroup were patients with ischemic stroke confirmed by brain computed tomography or magnetic resonance imaging; (3) the active treatment consisted of blood pressure lowering intervention. We included trials in which baseline antihypertensive were stopped in the control arm, whereas the intervention arm consisted of a trialspecific regimen ( 11 ). We also included trials in which baseline antihypertensive were continued as background therapy in both arms and an additional blood pressure regimen added to the intervention arm. (4) Reported outcome included dependency or death (modified Rankin Scale, 3-6 or nearest equivalent) or recurrent vascular events at 3 months or at the trial end point. All data from eligible trials were independently abstracted by 2 investigators (M.L. and K.-S.H.) according to standard protocol. Discrepancies were resolved by discussion with a third investigator (Y.-L.W.) and by referencing the original report.
Study Quality Assessment
Jadad score was used to assess study quality because all included studies were RCTs. 12 This 5-point scoring system evaluates the randomization process (2 questions), blinding (2 questions), and the description of withdrawals and dropouts (1 questions).
Statistical Analysis
The primary outcome was unfavorable outcome at 3 months or at trial end point, defined as dependency or death (modified Rankin Scale, 3-6 or nearest equivalent) if measured. The key secondary outcome was recurrent vascular events at 3 months or at trial end point. Additional outcomes of interest were disability or death (modified Rankin Scale, 2-6), death from any cause, and recurrent stroke at 3 or 6 months. We also looked at death or dependency, death or disability, all-cause mortality, and serious adverse events at 2 weeks or 1 month.
Data were analyzed according to the intention-to-treat principle. A random-effect estimate based on the Mantel-Haenszel method was computed when ≥2 studies provided sufficient data for a given outcome. Statistical heterogeneity was assessed using a χ 2 and the I 2 statistics. Study-level estimates were considered heterogeneous if either the χ 2 test was significant at the P=0.10 level or the I 2 statistic was >50%. Publication bias was assessed by visual examination of funnel plots. The Cochrane Collaboration's Review Manager Software Package (RevMen 5.2) was used for this meta-analysis.
Results
Of the 51 RCTs retrieved for detailed assessment, 38 were excluded for the following reasons: trials of intracranial hemorrhage-2; trials of neuroprotective drugs-2; end point different than specified in meta-analysis plan-25; and patients not enrolled within 3 days of stroke onset-8. One trial, Paramedic Initiated Lisinopril For Acute Stroke Treatment (PIL-FAST; 64% were ischemic stroke patients), was further excluded because a results in patients with ischemic stroke were not reported separately from those with intracranial hemorrhage or stroke-mimicking conditions (Figure 1) . 13 Our final analysis included 13 RCTs, [8] [9] [10] [11] [14] [15] [16] [17] [18] [19] [20] [21] comprising 12 703 individuals, with 6392 (50%) participants randomly assigned to the active treatment group and 6311 (50%) to the control group. The study design, quality, and baseline characteristics of these RCTs are shown in Tables 1 and 2 . Most trials were conducted in Europe, whereas 1 large trial was from China. Analyzed data were abstracted from whole trials that enrolled only patients with ischemic stroke (6 trials), 10, [14] [15] [16] [17] 19 separately reported subgroups of patients with ischemic stroke (6 trials), 9, 11, 18, [20] [21] [22] and a separately reported subgroup of patients with ischemic stroke enrolled within 72 hours (1 trial). 8 The median time from stroke onset to randomization ranged from 11 to 58 hours. The magnitude of lowering of blood pressure in active treatment groups, when compared with control groups, was reported in 5 trials at 24 hour, ranged from 0.3 to 8.1 mm Hg for systolic blood pressure and 1.8 to 9.4 mm Hg for diastolic blood pressure. The magnitude of lowering of systolic blood pressure in active treatment groups, when compared with control groups, was reported in 7 trials at day 7 or day 14, ranged from −3.5 to 20 mm Hg for systolic blood pressure and 0 to 9 mm Hg for diastolic blood pressure. Among 13 trials, 12 reported outcome for the primary end point analysis (ie, death or dependency) and 6 reported outcome for the key secondary end point (ie, recurrent vascular events) analysis. The overall quality of trials was good (Jadad score, median 4 points, ranged from 3-5).
Pooling the results from 12 trials with the random-effects model showed that blood pressure lowering in early ischemic stroke did not affect the risk of death or dependency at 3 months or at trial end point (relative risk, 1.04; 95% confidence interval, 0.96-1.13; P=0.35). There was significant heterogeneity among studies (I 2 =51%; P for heterogeneity=0.02; Figure 2 ). The funnel plots showed no major asymmetry (Figure 3) . For additional outcomes, blood pressure lowering also had neutral effect on recurrent vascular events, as well as on disability or death, all-cause mortality, recurrent stroke, and serious adverse events (Table 3 ).
Discussion
The current meta-analysis, which pooled data from all relevant trials with amalgamable outcome assessment, suggested that blood pressure lowering in early ischemic stroke did not affect the risk of death or dependency at 3 months. Also, the risks of recurrent vascular events, recurrent stroke, death, and serious adverse events were not different between active treatment and control groups. Hypertension is an important modifiable factor in the prevention of recurrent stroke, and these results suggest that the introduction of therapy in the subacute phase is not associated with harm.
The median time to initiation of blood pressure lowering was not earlier than 15 hours of stroke onset, and the duration of active treatment was within 2 weeks among most included trials. When blood pressure remained untreated during the first 2 weeks, the frequency of recurrent stroke was low at 3 to 6 months, affording little opportunity for active blood pressure reduction to improve outcome. Conversely, when blood pressure was actively treated in the subacute time period, there apparently was little risk of infarct extension and neurological deterioration because of failure of collateral circulation. 3 It is likely that the fate of the threatened penumbra has mostly been determined by 10 hours after onset. 23 These findings in patients with ischemic stroke contrast with those in intracerebral hemorrhage. A recent large trial, the second Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2), found a trend of benefit in reducing death or disability with early blood pressure lowering in intracranial hemorrhage. 24 Several pathophysiologic differences between ischemic and hemorrhagic brain injury may contribute to this distinction. Early after intracerebral hemorrhage onset, systolic blood pressure is substantially elevated compared with usual premorbid levels, whereas systolic blood pressure after major ischemic stroke is much closer to the long-term premorbid level, and treating the lesser deviation from baseline levels may have reduced physiological effects. 25, 26 In intracerebral hemorrhage, early hematoma expansion may be a physiological target more susceptible to alteration by blood pressure moderation than any of the mechanisms of early worsening in ischemic stroke. 27 Because most patients were not enrolled earlier than 15 hours of stroke onset, an important remaining unanswered question in blood pressure management in ischemic stroke involves the hyperacute period, within the first few hours after onset, when there is still substantial penumbral, at-risk tissue. Although The Field Administration of Stroke TherapyMagnesium (FAST-MAG) trial enrolled stroke patients within 2 hours of stroke onset and blood pressure lowering effect of magnesium may exist, yet this was a neuroprotective trial, so we chose to exclude this trial. 28 Full data sets from forthcoming trials, such as Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED), may help to resolve this remaining issue. 29 Some limitations of our study need to be mentioned. First, meta-analyses may be biased when the literature search fails to identify all relevant trials or the selection criteria for including a trial are applied in a subjective manner. To minimize these risks, we performed thorough searches across multiple literature databases and used explicit criteria for study selection, data abstraction, and data analysis. Second, because this is a study-level Relative risk with 95% confidence interval (CI) estimates for death or dependency (early blood pressure lowering vs control) at 3 months or at trial end point among patients with ischemic stroke.
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meta-analysis, we could not perform multivariate adjustment for differences in individual patient; an individual patient data meta-analysis, such as the ongoing plans of the Blood Pressure in Acute Stroke Collaboration, would be needed to mitigate this concern. Third, different types of stroke (large vessel, lacunar, embolic, etc) may have different response to blood pressure lowering but that was not captured in the analysis. Blood pressure lowering in acute stroke may impair the penumbra and worsen the neurological deficit differentially in large vessel stroke compared with lacunar stroke. Further studies for blood pressure lowering in acute stroke would benefit from careful subtyping of stroke mechanism and potentially from penumbral imaging to identify subpopulations with distinct responses to therapy.
In conclusion, this meta-analysis of completed clinical trials suggested blood pressure lowering in early ischemic stroke had a neutral effect on the prevention of death or dependency. Further studies with an appropriately phenotyped population that is recruited in the hyperacute phase of ischemic stroke are warranted. 
